Skip to main content
Figure 3 | Thrombosis Journal

Figure 3

From: Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring

Figure 3

Predicted plasma rivaroxaban concentration–time profiles for extremes in age, renal function and body weight. Patients receiving rivaroxaban 20 mg once daily. The simulated patients had typical mean characteristics (age 60 years, body weight 80 kg, CrCl 90 ml/min) unless specified otherwise [12]. CLCR/CrCl, creatinine clearance. Reproduced from Mueck W, Lensing AW, Agnelli G et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50:675–686 with permission from Adis (© Springer International Publishing AG 2011. All rights reserved).

Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us